Targeted treatment approaches in refractory germ cell tumors. (November 2019)

• Record Type: Journal Article
• Authors: Galvez-Carvajal, Laura; Sanchez-Muñoz, Alfonso; Ribelles, Nuria; Saez, Maribel; Baena, Javier; Ruiz, Sofia; Ithurbisquy, Catherine; Alba, Emilio
• Is Part Of: Critical reviews in oncology/hematology. Volume 143(2019)
• Page Start: 130
• Page End: 138
• Publication Date: 2019-11
• Subjects: Germ cell tumors -- Targeted therapy -- Testicular tumors; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2019.09.005
• Languages: English
• ISSNs: 1040-8428

Abstract

Highlights: Around 15-20% of metastatic patients will not have curative options after a relapse on the first and second line. No targeted treatment in GCTs has proved a reasonable efficiency. The future of the research lies in the appropriate selection of patients with a certain molecular profile. Abstract: Germ cell tumors (GCTs) are the most common type of solid tumor amongst patients between 15 and 35 years of age. They are also one of the types of tumor with the highest cure rate, due to their high sensitivity to cisplatin based chemotherapy. Nonetheless, around 15–20% of metastatic patients will not have curative options after a relapse on the first and second line. This proves that new therapeutic options for these refractory GCTs patients need to be developed. This article offers a bibliographic review of all studies using targeted treatment or immunotherapy for refractory GCTs patients.